For
immediate release
|
5 February
2024
|
ALLIANCE PHARMA
PLC
("Alliance", "Company" or the
"Group")
New Chair Appointment
Alliance Pharma plc (AIM: APH), the
international healthcare group, announces its plans for Board
evolution.
Alliance has transitioned from a
Prescription Medicines business to a fast growth Consumer
Healthcare company over recent years, with Consumer Healthcare
revenues representing 75% of Group revenues in 2023. Over the last
five years, Jo LeCouilliard has been instrumental in driving this
transition, first as a Non-Executive Director and, more recently,
as Chair. Under her leadership, the Company has strengthened the
Board, appointing two new directors with Consumer experience,
particularly in the APAC region. Jo and the Board feel that it is
now appropriate for her to step down from the Board and to appoint
a new Chair, with strong international Consumer Healthcare
experience, to lead the Company through its next strategic phase,
focusing on organic growth through marketing and
innovation.
The Board is pleased to announce
that Camillo Pane will be appointed to the Board and assume the
role of Chair on 19 February 2024 following a handover period from
Jo. Camillo has over thirty years' experience in US, European and
Asian public, multinational Consumer companies. During his career,
Camillo has held a number of senior positions at Reckitt Benckiser
where he spent almost 20 years across both Global and Regional
roles, including Senior Vice President and Global Category Officer
for Consumer Health, before moving to Coty Inc, one of the largest
beauty companies in the world, where, as CEO, he led the merger
with Procter & Gamble Specialty Beauty. Most recently, he was
Group CEO of Health & Happiness Group, a global Health and
Nutrition company listed on the Hong Kong Stock Exchange with
revenues of around $2bn.
Richard Jones, Senior Independent Director of Alliance,
commented:
"On behalf of the Alliance Board and
the Company I would like to thank Jo for her significant
contribution to Alliance over the past five years and wish her well
for the future. We look forward to Camillo joining the Board as
Chair and harnessing his wide-ranging consumer healthcare
experience to further enhance and develop our Group strategy. In
the meantime, the Board remains focused on creating value for our
shareholders by investing in growth whilst carefully managing our
cost base."
In
accordance with Schedule 2 (g) of the AIM Rules for Companies,
Camillo Pane (aged 53 years) holds/has held the following
directorships/partnerships in the last five
years:
Current directorships/partnerships
|
Previous directorships/partnerships (last five
years)
|
· VCP & Partners
Limited
· LSG Hydra
Limited
· Passione Beauty
s.p.a.
|
· Ocean Labs Beauty
Ltd
· Loum Holdings
Ltd
· Present Life
Ltd
· Kadenwood
Inc
|
Camillo Pane currently holds no ordinary shares in the
Company.
There are no further disclosures to made be under Schedule
2(g) of the AIM Rules for Companies.
For
further information:
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
Cora McCallum, Head of Investor
Relations & Corporate Communications
|
+ 44
(0)1249 705168
|
ir@allianceph.com
|
|
|
|
Buchanan
|
+ 44 (0)20 7466
5000
|
Mark Court / Sophie Wills
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0)20 7597
5970
|
Patrick Robb / Maria Gomez de
Olea
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com